Potent, selective and long-acting β2-adrenoceptor agonist. Displays 330-fold selectivity for β2 over β1 receptors (pKd values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 50 mM in DMSO|
References are publications that support the biological activity of the product.
Anderson (1993) Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci. 52 2145 PMID: 8099696
Decker et al (1982) Effects of N-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: pharmacological studies and binding assays. J.Pharm.Pharmacol. 34 107 PMID: 6121868
Naline et al (1994) Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur.Respir.J. 7 914 PMID: 7914176
If you know of a relevant reference for Formoterol hemifumarate, please let us know.
View Related Products by Product Action
Keywords: Formoterol hemifumarate, Formoterol hemifumarate supplier, Potent, selective, β2-adrenoceptor, α2-adrenoceptor, beta2-adrenoceptor, b2-adrenoceptor, β2-adrenergic, α2-adrenergic, beta2-adrenergic, b2-adrenergic, agonists, Receptors, BD40A, BD, 40A, Adrenergic, Beta-2, 1448, Tocris Bioscience
8 Citations for Formoterol hemifumarate
Citations are publications that use Tocris products. Selected citations for Formoterol hemifumarate include:
Bacou (2017) β2-adrenoreceptor stimulation dampens the LPS-induced M1 polarization in pig macrophages. Dev Comp Immunol 76 169 PMID: 28633932
Luo (2017) β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro. Scientific Reports 7 39905 PMID: 28051147
Lavine (2017) β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression. Invest Ophthalmol Vis Sci 58 299 PMID: 28114591
Maupoil et al (2007) Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1- and beta1-adrenoceptors. Br J Pharmacol 150 899 PMID: 17325650
Liu et al (2015) A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype-3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells. Mol Cell Neurosci 11 4121 PMID: 25672589
Pon et al (2016) The β2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. FASEB J 30 1144 PMID: 26578688
Plummer et al (2004) Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer 4 93 PMID: 15603589
Lavine et al (2013) Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism. JAMA Ophthalmol 131 376 PMID: 23303344
Do you know of a great paper that uses Formoterol hemifumarate from Tocris? Please let us know.
Reviews for Formoterol hemifumarate
There are currently no reviews for this product. Be the first to review Formoterol hemifumarate and earn rewards!
Have you used Formoterol hemifumarate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.